I've written extensively about Vertex and its hepatitis C drug telaprevir, a protease inhibitor that, so far, has shown very promising direct antiviral activity against the hepatitis C virus. (For that background, look
A series of clinical trials will test the combination of Bristol-Myers Squibb's Opdivo with Nektar's NKTR-214 in multiple tumor types.
Amgen's effort to improve disappointing sales of its multiple myeloma drug Kyprolis took a hit Tuesday with the failure of a phase III clinical trial involving newly diagnosed patients.
Kite Pharma's CAR-T therapy demonstrated a 39% response rate, including a 33% complete response rate, in patients with an aggressive form of lymphoma, the company said Tuesday.
Failure is very profitable for Pain Therapeutics CEO Remi Barbier.